You are browsing in:
Tag: Bedinvetmab
vet examine dog in clinic with client

Anti-nerve growth factor monoclonal antibodies – What is the evidence?

Published 29 May 2025 | Updated 29 July 2025 |
This feature brings together published evidence about the potential use of biomarkers in the diagnosis and management of cancer in veterinary patients and provides an overview of the types of tests currently available.

Vet examining a dog in a clinic

A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab , a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis

M.J. Corral, H. Moyaert, T. Fernandes, M. Escalada, J.K.S. Tena, R. R. Walters and M.R. Stegemann | Veterinary Anaesthesia and Analgesia | August 2021
The aim of this randomized, double-blind, multicentre study was to evaluate the efficacy and safety of bedinvetmab (Librela; Zoetis), compared to a placebo, for the alleviation of pain associated with osteoarthritis in client-owned dogs (n = 287)…

A Golden Retriever lying on a bed

Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs

M. Krautmann, R. Walters, P. Cole, J. Tena, L.M. Bergeron, J. Messamore, D. Mwangi, S. Rai, P. Dominowski, K. Saad, Y. Zhu, M. Guillot and L. Chouinard | The Veterinary Journal | October 2021
This paper describes the laboratory safety evaluation of bedinvetmab based on three integrated laboratory studies in healthy adult laboratory Beagles…